Circadian use of glucocorticoids in rheumatoid arthritis

NeuroImmunoModulation

Volumn 22, Issue , 2014, Pages 33-39

  Cutolo, Maurizio ^a   Sulli, Alberto ^a   Pincus, Theodore ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b RUSH UNIVERSITY   (United States)

Author keywords

Chronotherapy; Circadian rhythms; Cytokines; Disease modifying antirheumatic drugs; Glucocorticoids; Melatonin; Rheumatoid arthritis; Sleep

Indexed keywords

GLUCOCORTICOID; HYDROCORTISONE; INTERLEUKIN 6; PREDNISONE;

ADRENAL INSUFFICIENCY; ARTICLE; BEDTIME DOSAGE; CHRONOBIOLOGY; CHRONOTHERAPY; CIRCADIAN RHYTHM; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LONG TERM CARE; MORNING STIFFNESS; RHEUMATOID ARTHRITIS; SLEEP; ANIMAL; ARTHRITIS, RHEUMATOID; CHRONOBIOLOGY DISORDERS; COMPLICATION; DRUG EFFECTS; PHYSIOLOGY;

ANIMALS; ARTHRITIS, RHEUMATOID; CHRONOBIOLOGY DISORDERS; CIRCADIAN RHYTHM; GLUCOCORTICOIDS; HUMANS;

EID: 84908601953     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000362733     Document Type: Article

References (60)

1. McInnes IB, O'Dell JR: State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1898-1906.
2. Smolen JS, Landewe R, Breedveld FC, et al: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509.
3. Bakker MF, Jacobs JW, Welsing PM, et al: Low-dose prednisone inclusion in a methotrexate- based, tight control strategy for early rheumatoid arthritis: A randomized trial. Ann Intern Med 2012; 156: 329-339.
4. Gorter SL, Bijlsma JW, Cutolo M, et al: Current evidence for the management of rheumatoid arthritis with glucocorticoids: A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1010-1014.
5. Pincus T, Sokka T, Castrejon I, et al: Decline of mean initial prednisone dosage from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/day. Arthritis Care Res (Hoboken) 2013; 65: 729-736.
6. Wassenberg S, Rau R, Steinfeld P, et al: Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: A multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 3371-3380.
7. van der Goes MC, Jacobs JW, Boers M, et al: Patient and rheumatologist perspectives on glucocorticoids: An exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2010; 69: 1015-1021.
8. Strehl C, Spies CM, Buttgereit F: Pharmacodynamics of glucocorticoids. Clin Exp Rheumatol 2011; 29(5 suppl 68):S13-S18.
9. Cutolo M, Buttgereit F, Straub RH: Regulation of glucocorticoids by the central nervous system. Clin Exp Rheumatol 2011; 29(5 suppl 68):S19-S22.
10. Sierakowski S, Cutolo M: Morning symptoms in rheumatoid arthritis: A defining characteristic and marker of active disease. Scand J Rheumatol Suppl 2011; 125: 1-5.
11. Cutolo M: Rheumatoid arthritis: circadian and circannual rhythms in RA. Nat Rev Rheumatol 2011; 7: 500-502.
12. Straub RH, Cutolo M: Effects of the neuroendocrine system on development and function of the immune system; in Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds): Rheumatology, ed 5. Amsterdam, Elsevier, 2014, chap 25.
13. Crofford LJ, Kalogeras KT, Mastorakos G, et al: Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab 1997; 82: 1279-1283.
14. Lange T, Dimitrov S, Born J: Effects of sleep and circadian rhythm on the human immune system. Ann NY Acad Sci 2010; 1193: 48-59.
15. Straub RH, Cutolo M, Buttgereit F, et al: Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med 2010; 267: 543-560.
16. Chrousos GP: The hypothalamic-pituitaryadrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332: 1351-1362.
17. Haus EL, Smolensky MH: Shift work and cancer risk: potential mechanistic roles of circadian disruption, light at night, and sleep deprivation. Sleep Med Rev 2013; 17: 273-284.
18. Doane LD, Kremen WS, Eaves LJ, et al: Associations between jet lag and cortisol diurnal rhythms after domestic travel. Health Psychol 2010; 29: 117-123.
19. Kino T, Chrousos GP: Acetylation-mediated epigenetic regulation of glucocorticoid receptor activity: circadian rhythm-associated alterations of glucocorticoid actions in target tissues. Mol Cell Endocrinol 2011; 336: 23-30.
20. Pejovic S, Basta M, Vgontzas AN, et al: Effects of recovery sleep after one work week of mild sleep restriction on interleukin-6 and cortisol secretion and daytime sleepiness and performance. Am J Physiol Endocrinol Metab 2013; 305:E890-E896.
21. Bahijri S, Borai A, Ajabnoor G, et al: Relative metabolic stability, but disrupted circadian cortisol secretion during the fasting month of Ramadan. PLoS One 2013; 8:e60917.
22. Mullington JM, Haack M, Toth M, et al: Cardiovascular, inflammatory, and metabolic consequences of sleep deprivation. Prog Cardiovasc Dis 2009; 51: 294-302.
23. Straub RH, Bijlsma JW, Masi A, et al: Role of neuroendocrine and neuroimmune mechanisms in chronic inflammatory rheumatic diseases: The 10-year update. Semin Arthritis Rheum 2013; 43: 392-404.
24. Cutolo M: Chronobiology and the treatment of rheumatoid arthritis. Curr Opin Rheumatol 2012; 24: 312-318.
25. Cutolo M, Straub RH, Bijlsma JW: Neuroendocrine- immune interactions in synovitis. Nat Clin Pract Rheumatol 2007; 3: 627-634.
26. Cutolo M, Straub RH: Circadian rhythms in arthritis: hormonal effects on the immune/inflammatory reaction. Autoimmun Rev 2008; 7: 223-228.
27. Spies CM, Cutolo M, Straub RH, et al: More night than day - circadian rhythms in polymyalgia rheumatica and ankylosing spondylitis. J Rheumatol 2010; 37: 894-899.
28. Caporali R, Cimmino MA, Montecucco C, et al: Glucocorticoid treatment of polymyalgia rheumatica. Clin Exp Rheumatol 2011; 29(5 suppl 68):S143-S147.
29. Cutolo M, Foppiani L, Minuto F: Hypothalamic- pituitary-adrenal axis impairment in the pathogenesis of rheumatoid arthritis and polymyalgia rheumatica. J Endocrinol Invest 2002; 25(10 suppl):19-23.
30. Straub RH, Gluck T, Cutolo M, et al: The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumour necrosis factor) in polymyalgia rheumatica. Rheumatology 2000; 39: 624-631.
31. Bollinger T, Bollinger A, Naujoks J, et al: The influence of regulatory T cells and diurnal hormone rhythms on T helper cell activity. Immunology 2010; 131: 488-500.
32. Buttgereit F, Burmester GR, Straub RH, et al: Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum 2011; 63: 1-9.
33. Gorter SL, Bijlsma JW, Cutolo M, et al: Current evidence for the management of rheumatoid arthritis with glucocorticoids: A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1010-1014.
34. van der Goes MC, Jacobs JW, Boers M, et al: Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis 2010; 69: 1913-1919.
35. Cutolo M, Seriolo B, Craviotto C, et al: Circadian rhythms in RA. Ann Rheum Dis 2003; 62: 593-596.
36. Cutolo M, Otsa K, Aakre O, et al: Nocturnal hormones and clinical rhythms in rheumatoid arthritis. Ann NY Acad Sci 2005; 1051: 372-381.
37. Jacobs JW, Bijlsma JW: Modified release prednisone in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1257- 1259.
38. Spies CM, Cutolo M, Straub RH, et al: Prednisone chronotherapy. Clin Exp Rheumatol 2011; 29(5 suppl 68):S42-S45.
39. Alten R, Doring G, Cutolo M, et al: Hypothalamus- pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. J Rheumatol 2010; 37: 2025-2031.
40. Buttgereit F, Doering G, Shaeffler A, et al: Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): A double-blind, randomised controlled trial. Lancet 2008; 371: 205-214.
41. Buttgereit F, Doering G, Schaeffler A, et al: Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1275-1280.
42. Kirwan JR, Hickey SH, Hallgren R, et al: The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 1415-1421.
43. To H, Irie S, Tomonari M, et al: Therapeutic index of methotrexate depends on circadian cycling of tumour necrosis factor-α in collagen- induced arthritic rats and mice. J Pharm Pharmacol 2009; 61: 1333-1338.
44. To H, Yoshimatsu H, Tomonari M, Ida H, et al: Methotrexate chronotherapy is effective against rheumatoid arthritis. Chronobiol Int 2011; 28: 267-274.
45. Debbono M, Ross RJ: Optimal glucocorticoid therapy. Endocr Dev 2011; 20: 173-180.
46. Langenheim J, Ventz M, Hinz A, et al: Modified- release prednisone decreases complaints and fatigue compared to standard prednisolone in patients with adrenal insufficiency. Horm Metab Res 2013; 45: 96-101.
47. Baker DE: Budesonide modified-release capsules. Rev Gastroenterol Disord 2001; 1: 147-155.
48. Derendorf H, Ruebsamen K, Clarke L, et al: Pharmacokinetics of modified-release prednisone tablets in healthy subjects and patients with rheumatoid arthritis. J Clin Pharmacol 2013; 53: 326-333.
49. Pfeiffer BM, Krenzer S, Dockhorn R, et al: Impact of modified-release prednisone on functional ability in patients with rheumatoid arthritis. Rheumatol Int 2013; 33: 1447-1454.
50. Cutolo M, Iaccarino L, Doria A, et al: Efficacy of the switch to modified-release prednisone in rheumatoid arthritis patients treated with standard glucocorticoids. Clin Exp Rheumatol 2013; 31: 498-505.
51. Dunlop W, Iqbal I, et al: Cost-effectiveness of modified-release prednisone in the treatment of moderate to severe rheumatoid arthritis with morning stiffness based on directly elicited public preference values. Clinicoecon Outcomes Res 2013; 5: 555-564.
52. Boers M, Buttgereit F: A simple model that suggests possible cost savings when modified release prednisone 5 mg/day is added to current treatment in patients with active rheumatoid arthritis. Rheumatology (Oxford) 2013; 52: 1435-1437.
53. Pincus T, Castrejon I, Yazici Y: Low-dose prednisone inclusion in a methotrexatebased, tight control strategy for early rheumatoid arthritis. Ann Intern Med 2012; 157: 299.
54. Levi F, Le Louarn C, Reinberg A: Timing optimizes sustained-release indomethacin treatment of osteoarthritis. Clin Pharmacol Ther 1985; 37: 77-84.
55. Pincus T, Bijlsma JW, Braun J, et al: Low-dose glucocorticoids in rheumatic diseases: introduction. Clin Exp Rheumatol 2011; 29(5 suppl 68):S2-S4.
56. De Silva M, Binder A, Hazleman BL: The timing of prednisolone dosage and its effect on morning stiffness in rheumatoid arthritis. Ann Rheum Dis 1984; 43: 790-793.
57. Arvidson NG, Gudbjornsson B, Elfman L, et al: Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 521-524.
58. Arvidson NG, Gudbjornsson B, Larsson A, et al: The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis 1997; 56: 27-31.
59. Da Silva JA: Safety of glucocorticoids - clinical trials. Clin Exp Rheumatol 2011; 29(5 suppl 68):S99-S103.
60. LaRochelle GE Jr, LaRochelle AG, Ratner RE, Borenstein DG: Recovery of the hypothalamic- pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. Am J Med 1993; 95: 258-264.